1,582 reports of this reaction
3.4% of all MECLIZINE HYDROCHLORIDE reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for MECLIZINE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 1,582 FDA adverse event reports linking MECLIZINE HYDROCHLORIDE to FATIGUE. This represents approximately 3.4% of all 45,890 adverse event reports for this drug.
Patients taking MECLIZINE HYDROCHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among MECLIZINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for MECLIZINE HYDROCHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 1,582 FDA reports for MECLIZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.4% of all adverse event reports for MECLIZINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience fatigue while taking MECLIZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.